Research

The preparation is currently thoroughly studied in several research centers in Poland.

The National Medicines Institute in cooperation with the Dept. of Bioanalysis and Drugs Analysis, the Dept. of Biochemistry and Clinical Chemistry of Warsaw Medical University, Faculty of Biology of Warsaw University, Institute of Physics Polish Academy of Sciences, Collegium Medicum of Jagiellonian University, Medical Research Centre of Polish Academy of Sciences, National Veterinary Research Institute in Puławy, Instytute of Industrial Organic Chemistry Branch Pszczyna and the University of Warmia and Mazury in Olsztyn have been carrying out research on the mechanisms of action and the potential usage of the original Polish invention, SELOL (stg25), in medical treatment.
New research centres from all over the world are joining in. In 2013 international studies financed by the European Union are being conducted on the preparation. They are carried out at universities in Brazil, China, Germany, Norway, Finland, Spain, Portugal and Poland.
For several years now, our scientists have been cooperating with two universities in Brasil (Sao Oaulo and Brasilia). We will continue and expand the research regarding „intelligent” magnetic nanoparticles containing SELOL. Preliminary studies have shown a four times bigger increase in cytotoxicity of SELOL in form of nanoparticles with respect to many cancer cell lines. The maghemite magnetic nanoparticles with SELOL recognize cancer cells, enter them and release SELOL.
Moreover, with the use of magnetic field, they can be accumulated in a chosen section of an organism, and after entering cancer cells, treated with alternating magnetic field, they can increase their temperature to 43oC (hyperthermia effect), which effectively destroys cancer cells.
The studies into SELOL activity on prostate cancer cells engrafted in laboratory animals have shown an approx 17% decrease in tumor within 14 days of SELOL supplementation.
The lethal dose of selenitetriglycerides administered orally in rats is 100mg/kg b.m., while in mice 168 mg/kg b.m.In subcutaneous administration of selenitetriglycerides in rats, no toxicity was recorded even in a dose of 500 mg/kg b.m.
A fourteen-day supplementation with selenitetriglycerides, conducted at the Faculty of Veterinary Medicine at University of Warmia and Mazury in Olsztyn, in a group of 6 cows in the third lactation stage (90-105 days of lactation) showed an increase in the concentration of selenium in the blood serum The concentration of selenium in the blood on day “0” (before administration of selenitetriglycerides) was 67.17 μg/l, the second day: 131.17 μg/l, after 6 days 228.30 μg/l. The study after 14 days showed a persistent serum concentration of selenium at the level of 258.57 μg/l, after 28 - 136.83 μg/l. Studies have shown that the digestive tract of ruminants exhibits a high assimilability of STG25 and shows the best affinity for tissues Based on the results of toxicity tests conducted in rats (examinations clinical, clinical-chemical, post-mortem, histophatological) with repeated 90-day oral administration of the test material (SELOL) in different doses: 2, 8 and 32 mg of Se(IV)/kg body mass, the no-observed-adverse-effect level (NOAEL) was 2 mg/kg b.m.
We have never recorded the slightest damage in organs during the treatment with selenitetriglycerides.